Icon Plc (NASDAQ:ICLR) – William Blair lifted their Q1 2018 EPS estimates for shares of Icon in a report released on Tuesday, Zacks Investment Research reports. William Blair analyst J. Kreger now forecasts that the medical research company will earn $1.44 per share for the quarter, up from their previous forecast of $1.43. William Blair also issued estimates for Icon’s Q2 2018 earnings at $1.47 EPS and Q3 2018 earnings at $1.47 EPS.
ICLR has been the subject of a number of other reports. Credit Suisse Group reiterated an “outperform” rating and set a $120.00 price target (up from $105.00) on shares of Icon in a report on Monday, October 16th. Zacks Investment Research upgraded shares of Icon from a “sell” rating to a “hold” rating and set a $128.00 price target for the company in a report on Wednesday, October 11th. KeyCorp reiterated an “overweight” rating and set a $125.00 price target (up from $115.00) on shares of Icon in a report on Monday, November 13th. They noted that the move was a valuation call. SunTrust Banks reiterated a “buy” rating and set a $133.00 price target on shares of Icon in a report on Monday, January 22nd. Finally, ValuEngine upgraded shares of Icon from a “hold” rating to a “buy” rating in a report on Sunday, December 31st. One analyst has rated the stock with a sell rating, three have assigned a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the stock. The company has a consensus rating of “Buy” and a consensus target price of $124.55.
Icon (NASDAQ ICLR) traded down $4.81 during trading hours on Wednesday, reaching $106.93. 461,291 shares of the company’s stock traded hands, compared to its average volume of 316,539. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.90 and a quick ratio of 1.90. Icon has a 52-week low of $76.46 and a 52-week high of $124.48. The stock has a market cap of $5,930.73 and a P/E ratio of 21.07.
Several institutional investors and hedge funds have recently added to or reduced their stakes in ICLR. Acrospire Investment Management LLC boosted its position in shares of Icon by 20.1% in the second quarter. Acrospire Investment Management LLC now owns 1,195 shares of the medical research company’s stock worth $117,000 after acquiring an additional 200 shares during the last quarter. SG Americas Securities LLC acquired a new position in Icon during the third quarter valued at approximately $148,000. C M Bidwell & Associates Ltd. acquired a new position in Icon during the fourth quarter valued at approximately $196,000. Advisor Partners LLC acquired a new position in Icon during the fourth quarter valued at approximately $201,000. Finally, Dean Capital Investments Management LLC acquired a new position in Icon during the fourth quarter valued at approximately $203,000. 89.60% of the stock is currently owned by institutional investors and hedge funds.
TRADEMARK VIOLATION WARNING: “William Blair Weighs in on Icon Plc’s Q1 2018 Earnings (NASDAQ:ICLR)” was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this piece of content on another site, it was stolen and reposted in violation of United States & international trademark and copyright legislation. The legal version of this piece of content can be read at https://www.dispatchtribunal.com/2018/02/03/icon-plc-iclr-expected-to-earn-q1-2018-earnings-of-1-44-per-share.html.
Icon Company Profile
ICON public limited company is a contract research organization (CRO), which is engaged in providing outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company is engaged in the strategic development, management and analysis of programs that support the various stages of the clinical development process, from compound selection to Phase I-IV clinical studies.
Get a free copy of the Zacks research report on Icon (ICLR)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Icon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icon and related companies with MarketBeat.com's FREE daily email newsletter.